Enterococcus (VRE) has become an important nosocomial pathogen because of its rapid spread, limited therapy options, mortality, and the possibility of transfer of vancomycin resistance to other pathogens such as Staphylococcus aureus. Vancomycinresistant E. faecium (VREF) and E. faecalis were first described in 1988 (1,2).They have become major nosocomial pathogens, but their prevalence in Latin America has remained <2 % (3). In Mexico, VRE has rarely been reported (4,5). In a recent stud
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.